Dr. Sujuan Ba serves as the President and COO of the National Foundation for Cancer Research (NFCR) and a Principal of the Adaptive Innovative Medical High-Impact Initiative (AIM HI), an oncology startup commercialization fund. Dr. Ba is also the founder and CEO of the Asian Fund for Cancer Research; a co-founder of the AGILE Research Foundation and the International Cancer Impact Fund; and the former President of the Chinese Biopharmaceutical Association. In 2017, she was recognized by the Chinese Medical Doctor Association for her outstanding contributions to international cooperation and was named one of the “Top 300 Women Leaders in Global Health” in 2015 by the Graduate Institute of International and Development Studies’ Global Health Programme.

In 2006, Dr. Ba led the NFCR to establish the international Szent-Györgyi Prize for Progress in Cancer Research, awarded annually in recognition of outstanding scientific achievement in the war against cancer. She has served continuously as co-chair of the Prize Selection Committee, which is comprised of academic leaders and pharmaceutical industry executives. The prize has become one of the premier cancer research awards in the world.

Dr. Ba serves on the International Consulting Committee of the China National Research Center for Translational Medicine (Shanghai).  She sits on the Scientific Advisory Boards of Medelis, Inc. (Fountain Hills, Arizona), and Immunicom Inc. (San Diego).  She currently serves on the Editorial Board of the Chinese Journal of Cancer and formerly served on the Membership Committee of the International Union against Cancer (Geneva) and the Activity Steering Committee of the Cosmos Club (Washington, DC).  Dr. Ba also belongs to BayHelix, an invitation-only organization of leaders of Chinese origin involved globally in life sciences and health (San Francisco, Shanghai, and Beijing).

Dr. Ba received a B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.

Learn more about Dr. Sujuan Ba here.